CN Patent

CN119241540A — Fgfr抑制剂的固体形式和其制备方法

Assigned to Incyte Corp · Expires 2025-01-03 · 1y expired

What this patent protects

本公开涉及化合物(1)：3‑(2,6‑二氟‑3,5‑二甲氧基苯基)‑1‑乙基‑8‑(吗啉‑4‑基甲基)‑1,3,4,7‑四氢‑2H‑吡咯并[3',2':5,6]吡啶并[4,3‑d]嘧啶‑2‑酮的固体形式和多晶型物、其制备方法以及其制备中的中间物，所述物质可用于治疗FGFR相关或介导的疾病，诸如癌症。

USPTO Abstract

本公开涉及化合物(1)：3‑(2,6‑二氟‑3,5‑二甲氧基苯基)‑1‑乙基‑8‑(吗啉‑4‑基甲基)‑1,3,4,7‑四氢‑2H‑吡咯并[3',2':5,6]吡啶并[4,3‑d]嘧啶‑2‑酮的固体形式和多晶型物、其制备方法以及其制备中的中间物，所述物质可用于治疗FGFR相关或介导的疾病，诸如癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN119241540A
Jurisdiction
CN
Classification
—
Expires
2025-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.